title: Relationship of the asthma control test with pulmonary function and exhaled nitric oxide.
abstract: BACKGROUND
  The Asthma Control Test (ACT) is a short, simple, patient-based tool for identifying patients with poorly controlled asthma; however, its value in practice has yet to be demonstrated.
  
  
  OBJECTIVE
  To clarify the relationship of ACT scores and clinical parameters, including pulmonary function tests, peak expiratory flow (PEF) indices, and exhaled nitric oxide (eNO) levels.
  
  
  METHODS
  The study included 105 patients with asthma who underwent routine checkups by asthma specialists since September 1, 2006, through January 31, 2007. All patients had been taking inhaled corticosteroids with or without other medications for asthma for at least 3 months. The patients completed the ACT questionnaire and underwent testing for eNO and spirometry. PEF indices, including PEF percentage of predicted value (%PEF), lowest PEF during 1 week expressed as a percentage of the highest PEF (Min%Max PEF), and PEF variability, were also analyzed in patients undergoing PEF monitoring.
  
  
  RESULTS
  The ACT scores ranged from 8 to 25 (median, 24), and total control was obtained in 45 patients (42.8%). The PEF indices and eNO values in the total control group were significantly better than those in the less controlled groups. However, the ACT scores were weakly correlated with percentage of predicted forced expiratory volume in 1 second (r = 0.219), %PEF (r = 0.387), Min%Max PEF (r = 0.354), PEF variability (r = -0.351), and eNO values (r = -0.310). Total control of ACT included uncontrolled conditions in physiologic and inflammatory parameters.
  
  
  CONCLUSIONS
  ACT should be used in combination with pulmonary function tests and/or eNO measurements.
authors.affiliation: Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan. tmjkshi@general-hosp.pref.shizuoka.jp
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Shirai
authors.forename: Kazuki
authors.initials: K
authors.lastname: Furuhashi
authors.forename: Takafumi
authors.initials: T
authors.lastname: Suda
authors.forename: Kingo
authors.initials: K
authors.lastname: Chida
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology*; D003937:Diagnosis, Differential; D045853:Exhalation; D005260:Female; D006801:Humans; D008297:Male; D054539:Medication Therapy Management; D008875:Middle Aged; D009569:Nitric Oxide / Q000032:analysis*; D012129:Respiratory Function Tests; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D009569:Nitric Oxide